CR20120318A - Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a - Google Patents

Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a

Info

Publication number
CR20120318A
CR20120318A CR20120318A CR20120318A CR20120318A CR 20120318 A CR20120318 A CR 20120318A CR 20120318 A CR20120318 A CR 20120318A CR 20120318 A CR20120318 A CR 20120318A CR 20120318 A CR20120318 A CR 20120318A
Authority
CR
Costa Rica
Prior art keywords
ary
triazol
pde10a inhibitors
heteroaromatic derivatives
enzyme
Prior art date
Application number
CR20120318A
Other languages
English (en)
Inventor
Ask Pueschl
Jacob Nielsen
Jan Kehler
John P Kilburn
Mauro Marigo
Morten Langgaard
Original Assignee
H Lundbeck & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck & Co As filed Critical H Lundbeck & Co As
Publication of CR20120318A publication Critical patent/CR20120318A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se dirige a compuestos, que son inhibidores de la enzima PDE10A. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de la invención y un portador farmacéuticamente aceptable.
CR20120318A 2009-12-17 2012-06-12 Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a CR20120318A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28732109P 2009-12-17 2009-12-17
DKPA200901340 2009-12-17

Publications (1)

Publication Number Publication Date
CR20120318A true CR20120318A (es) 2012-08-16

Family

ID=44246811

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120318A CR20120318A (es) 2009-12-17 2012-06-12 Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a

Country Status (36)

Country Link
US (2) US8501795B2 (es)
EP (1) EP2513106B1 (es)
JP (1) JP6035149B2 (es)
KR (1) KR101779629B1 (es)
CN (1) CN102753550B (es)
AR (1) AR079496A1 (es)
AU (1) AU2010333438B2 (es)
BR (1) BR112012014486A2 (es)
CA (1) CA2783728C (es)
CO (1) CO6602117A2 (es)
CR (1) CR20120318A (es)
CY (1) CY1116361T1 (es)
DK (1) DK2513106T3 (es)
DO (1) DOP2012000169A (es)
EA (1) EA021606B1 (es)
ES (1) ES2442179T3 (es)
GE (1) GEP20146201B (es)
GT (1) GT201200193A (es)
HR (1) HRP20131210T1 (es)
IL (1) IL220328A (es)
MA (1) MA33923B1 (es)
MX (1) MX2012006715A (es)
MY (1) MY156520A (es)
NZ (1) NZ600365A (es)
PH (1) PH12012501202A1 (es)
PL (1) PL2513106T3 (es)
PT (1) PT2513106E (es)
RS (1) RS53101B (es)
SG (1) SG181672A1 (es)
SI (1) SI2513106T1 (es)
SM (1) SMT201400009B (es)
TN (1) TN2012000278A1 (es)
TW (1) TWI487705B (es)
UA (1) UA107950C2 (es)
WO (1) WO2011072697A1 (es)
ZA (1) ZA201204420B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
CA2846758C (en) * 2011-09-19 2017-09-12 F. Hoffmann-La Roche Ag Triazolopyridine compounds as pde10a inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
CN104364249B (zh) 2012-05-30 2018-04-17 霍夫曼-拉罗奇有限公司 作为pde10抑制剂的三唑并化合物
KR20150021120A (ko) 2012-06-19 2015-02-27 선오비온 파마슈티컬스 인코포레이티드 헤테로아릴 화합물 및 이의 이용 방법
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2919781B1 (en) 2012-11-15 2017-06-28 Merck Sharp & Dohme Corp. Cyclobutyl benzimidazoles as pde10 inhibitors
CA2930293A1 (en) * 2013-11-28 2015-06-04 F. Hoffmann-La Roche Ag Imidazole derivatives
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN114671874B (zh) * 2021-08-30 2024-02-02 济南爱思医药科技有限公司 一种具有抗肿瘤活性的茶碱乙酸衍生物及其制备方法与应用
US20250034112A1 (en) * 2021-10-13 2025-01-30 Yale University Improved selective jak2 inhibitors and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1462521A (en) 1974-02-11 1977-01-26 Wyeth John & Brother Ltd Triazole derivatives
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
US6699853B2 (en) 1997-06-16 2004-03-02 Hoechst Schering Agrevo Gmbh 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides
SE9802937D0 (sv) 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
WO2004041258A2 (fr) 2002-10-30 2004-05-21 Neuro3D Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
KR20060030483A (ko) 2003-06-30 2006-04-10 알타나 파마 아게 Ｐｄｅ10 억제제로서 피롤로디히드로이소퀴놀린
CA2530114A1 (en) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
JP2007523152A (ja) 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
EP1755611A1 (en) * 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8492394B2 (en) * 2006-07-10 2013-07-23 H. Lundbeck A/S (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
GB0800411D0 (en) 2008-01-10 2008-02-20 Glaxo Group Ltd Novel compounds
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
CA2800618C (en) * 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof

Also Published As

Publication number Publication date
DOP2012000169A (es) 2012-12-15
HK1177745A1 (en) 2013-08-30
DK2513106T3 (da) 2014-01-13
ZA201204420B (en) 2013-09-25
GT201200193A (es) 2013-09-26
GEP20146201B (en) 2014-11-25
TWI487705B (zh) 2015-06-11
MX2012006715A (es) 2012-07-03
US8785653B2 (en) 2014-07-22
NZ600365A (en) 2013-10-25
EA021606B1 (ru) 2015-07-30
ES2442179T3 (es) 2014-02-10
CO6602117A2 (es) 2013-01-18
TN2012000278A1 (en) 2013-12-12
JP2013514286A (ja) 2013-04-25
SI2513106T1 (sl) 2014-01-31
US20130281459A1 (en) 2013-10-24
TW201130834A (en) 2011-09-16
CN102753550A (zh) 2012-10-24
AU2010333438A1 (en) 2012-06-21
MA33923B1 (fr) 2013-01-02
PT2513106E (pt) 2014-01-20
PH12012501202A1 (en) 2021-06-23
HRP20131210T1 (hr) 2014-01-17
SG181672A1 (en) 2012-07-30
WO2011072697A1 (en) 2011-06-23
KR20120113215A (ko) 2012-10-12
CY1116361T1 (el) 2017-02-08
AR079496A1 (es) 2012-02-01
MY156520A (en) 2016-02-26
UA107950C2 (en) 2015-03-10
EA201290517A1 (ru) 2012-12-28
IL220328A (en) 2014-12-31
IL220328A0 (en) 2012-08-30
US20120309764A1 (en) 2012-12-06
KR101779629B1 (ko) 2017-09-18
EP2513106A1 (en) 2012-10-24
CN102753550B (zh) 2015-03-25
RS53101B (sr) 2014-06-30
CA2783728C (en) 2018-06-12
PL2513106T3 (pl) 2014-09-30
JP6035149B2 (ja) 2016-11-30
BR112012014486A2 (pt) 2017-04-04
EP2513106B1 (en) 2013-11-06
SMT201400009B (it) 2014-03-07
US8501795B2 (en) 2013-08-06
CA2783728A1 (en) 2011-06-23
AU2010333438B2 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
CR20120317A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
CR20120319A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
GEP20146202B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
MY184008A (en) Aryl pyridine as aldosterone synthase inhibitors
CO6321263A2 (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
ECSP12011793A (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene
GEP20146201B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
WO2011033265A8 (en) Pharmaceutical compounds
EA200901319A1 (ru) Композиции для назального введения
EA201200390A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
BR112012011328A2 (pt) inibidores de akt
MX2011012199A (es) Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
ECSP13012698A (es) Derivados de imidazol como inhibidores de la enzima pde10a
NI201100024A (es) [ 4 - ( 5 - aminometil - 2 - fluoro - fenil ) - piperidin -1- il ] - [ 17-fluor0 - 1 - (2 - metoxi - etil ) - 4 - trifluorometoxi - 1h - indol - 3 - il] - metanona como un inhibidor de la triptasa de mastocitos.
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
UY32852A (es) [4-(5-aminometil-fenil)-piperidin-1-il]-1h-indol-3-il]-metanonas disustituidas.
EA200900137A1 (ru) Комбинация ингибитора if-каналов синусного узла и бета-блокатора
EA201190243A1 (ru) Стабильная фармацевтическая композиция флударабина фосфата
TN2011000573A1 (en) Aryl pyridine as aldosterone synthase inhibitors
CL2012001588A1 (es) Compuestos derivados de heteroaril triazoles, inhibidores de enzima pde10a; composicion farmaceutica; y su uso en el tratamiento de un trastorno neurodegenerativo o psiquiatrico, en el tratamiento de una adiccion a las drogas como alcohol, anfetaminas, cocaina u opiaceos.
CO6700886A2 (es) Derivados de imidazol como inhibidores de la enzima pde10a
EA201390464A1 (ru) Способ сухой обработки атазанавира